Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04085029

Enrollment

300

Registered

2019-09-11

Start date

2019-09-26

Completion date

2029-09-01

Last updated

2026-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic Cancer, Oligometastasis

Keywords

Ablative radiotherapy

Brief summary

The purpose of this study is to provide a registry of participants in order to assess the acute adverse event rates following ablative radiotherapy for metastatic disease.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age ≥ 18 years of age * Radiographic evidence of metastatic disease (may include oligoprogression, oligorecurrence or oligometastasis) at the time of study enrollment * Planned to receive, currently receiving, or have completed hypofractionated image guided radiotherapy (ablative radiotherapy) to an extracranial site(s) * Patient must sign study-specific informed consent

Exclusion criteria

• None

Design outcomes

Primary

Measure	Time frame
Occurrence of acute adverse events following radiotherapy	90 Days

Countries

United States

Contacts

CONTACTClinical Trials Office

RadOnc-Clinical_Trials@dm.duke.edu(919) 668 3726

PRINCIPAL_INVESTIGATORJoseph Salama, MD

Duke University

Outcome results